Hidvegi Tunda, Mukherjee Amitava, Ewing Michael, Kemp Carolyn, Perlmutter David H
Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA.
Methods Enzymol. 2011;499:33-54. doi: 10.1016/B978-0-12-386471-0.00003-1.
In the classical form of alpha-1-antitrypsin (AT) deficiency, a mutant protein accumulates in the endoplasmic reticulum of liver cells, causing hepatic fibrosis and hepatocellular carcinoma by a gain-of-toxic function mechanism. Autophagy is specifically activated by the accumulation of mutant AT, and the autophagy plays a key role in intracellular degradation of this mutant protein. Our recent study indicates that an autophagy enhancer drug can decrease the hepatic load of mutant AT and reduce hepatic fibrosis in a mouse model of AT deficiency. In this chapter, we discuss what is known about autophagy in AT deficiency and methods for characterizing autophagy in cell lines and animal models.
在α-1-抗胰蛋白酶(AT)缺乏症的经典形式中,一种突变蛋白在肝细胞的内质网中积累,通过毒性功能获得机制导致肝纤维化和肝细胞癌。自噬由突变型AT的积累特异性激活,并且自噬在这种突变蛋白的细胞内降解中起关键作用。我们最近的研究表明,一种自噬增强药物可以降低AT缺乏小鼠模型中突变型AT的肝脏负荷并减轻肝纤维化。在本章中,我们讨论了关于AT缺乏症中自噬的已知情况以及在细胞系和动物模型中表征自噬的方法。